Tango Therapeutics, Inc. (TNGX) Stock Price & Analysis
Tango Therapeutics, Inc. (TNGX) fell 2.99% to USD 26.63 as of July 25, 2026 at 03:47 UTC, according to Nexqual real-time market data.
TNGX last closed at USD 27.45; the session ranged USD 26.26–27.67 on volume of 2,430,615 shares. Market capitalization is $4.34B, with a 52-week range of USD 5.77–34.39 (NGM). Source: Nexqual, July 25, 2026 at 03:47 UTC.
Key Statistics (as of July 25, 2026 at 03:47 UTC)
| Price | USD 26.63 |
|---|---|
| Change | ▼ 2.99% (down) |
| Previous Close | USD 27.45 |
| Open | USD 27.5 |
| Day Range | USD 26.26 – 27.67 |
| 52-Week Range | USD 5.77 – 34.39 |
| Volume | 2,430,615 shares |
| Market Cap | $4.34B |
| Exchange | NGM |
Technical Analysis (TNGX)
Nexqual's technical model rates TNGX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:47 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.03 (neutral) |
| vs SMA50 | Below (USD 26.95) |
| MACD | -0.1 (negative) |
Analyst Ratings (TNGX)
Wall Street analysts rate TNGX "Strong Buy" based on 12 analysts, with a mean price target of USD 44.33 (range USD 24–69), per Nexqual as of July 25, 2026 at 03:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 44.33 |
| High Target | USD 69 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 12 / 1 / 0 |
Earnings (TNGX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.31 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.33 ▲ beat |
| 2025-09-30 | USD 0.13 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.35 vs est -0.34 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Financials & Fundamentals (TNGX)
| Total Revenue | $56.99M |
|---|---|
| Gross Margin | -126.80% |
| Operating Margin | -206.22% |
| Profit Margin | -188.15% |
| ROE | -38.42% |
| Debt / Equity | 8.38 |
| Current Ratio | 27.38 |
| Total Cash | $379.84M |
| Total Debt | $32.79M |
| Free Cash Flow | $-68.23M |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Financial Health Score (TNGX)
Nexqual rates Tango Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:47 UTC.
| Growth | Strong — Revenue +48% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $380M cash vs $33M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$68M, burning cash |
| Efficiency | Critical — ROE -38%, ROA -20.7% |
Ownership (TNGX)
| Insider Ownership | +1.17% |
|---|---|
| Institutional Ownership | +114.44% |
| Shares Outstanding | 162.81M |
| Float | 69.56M |
| Short % of Float | +26.10% |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
Leadership (TNGX)
Tango Therapeutics, Inc. is led by Malte Peters (age 63), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:47 UTC.
| President, CEO & Director | Malte Peters (age 63) |
|---|---|
| Founder & Executive Chairman of the Board | Barbara L. Weber (age 68) |
| President of Research & Development | Adam S. Crystal (age 48) |
| Chief Financial Officer | Matthew Gall (age 48) |
| Chief Scientific Officer | Jannik N. Andersen |
Major Backers & Investors (TNGX)
Notable institutional backers of Tango Therapeutics, Inc. include RTW Investments LP, Adage Capital Partners GP L.L.C., Boxer Capital Management, LLC, according to Nexqual as of July 25, 2026 at 03:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.2% |
| Adage Capital Partners GP L.L.C. | 8.86% |
| Boxer Capital Management, LLC | 7.52% |
| TCG Crossover Management, LLC | 7.28% |
| FMR, LLC | 6.85% |
| Farallon Capital Management LLC | 6.29% |
| Woodline Partners LP | 5.53% |
| Nextech Invest, Ltd. | 5.02% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.01% |
Source: Nexqual, July 25, 2026 at 03:47 UTC.
From Tango Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
- The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
- It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ERAS | Erasca, Inc. | USD 19.11 | ▼ 2.05% |
| TYRA | Tyra Biosciences, Inc. | USD 30.63 | ▲ 0.13% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
| RLAY | Relay Therapeutics, Inc. | USD 18.44 | ▼ 4.31% |
| TVTX | Travere Therapeutics, Inc. | USD 57.36 | ▲ 1.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:47 UTC. This page is informational and not investment advice.